Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
141.31
+4.64 (3.40%)
Jan 21, 2025, 4:00 PM EST - Market closed
Illumina Employees
Illumina had 13,360 employees as of December 31, 2023. The number of employees increased by 1,610 or 13.70% compared to the previous year.
Employees
13,360
Change (1Y)
1,610
Growth (1Y)
13.70%
Revenue / Employee
$328,593
Profits / Employee
-$118,638
Market Cap
22.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13,360 | 1,610 | 13.70% |
Dec 31, 2022 | 11,750 | 2,400 | 25.67% |
Dec 31, 2021 | 9,350 | 1,500 | 19.11% |
Dec 31, 2020 | 7,850 | 150 | 1.95% |
Dec 29, 2019 | 7,700 | 400 | 5.48% |
Dec 30, 2018 | 7,300 | 1,100 | 17.74% |
Dec 31, 2017 | 6,200 | 700 | 12.73% |
Dec 31, 2016 | 5,500 | 900 | 19.57% |
Dec 31, 2015 | 4,600 | 900 | 24.32% |
Dec 28, 2014 | 3,700 | 700 | 23.33% |
Dec 29, 2013 | 3,000 | 800 | 36.36% |
Dec 31, 2012 | 2,200 | -200 | -8.33% |
Dec 30, 2012 | 2,400 | 300 | 14.29% |
Dec 31, 2011 | 2,100 | 319 | 17.91% |
Dec 31, 2010 | 1,781 | 245 | 15.95% |
Dec 28, 2008 | 1,536 | 495 | 47.55% |
Dec 30, 2007 | 1,041 | 445 | 74.66% |
Dec 31, 2006 | 596 | 221 | 58.93% |
Dec 31, 2006 | 375 | 97 | 34.89% |
Dec 31, 2005 | 278 | 42 | 17.80% |
Dec 28, 2003 | 236 | 3 | 1.29% |
Dec 29, 2002 | 233 | 54 | 30.17% |
Dec 30, 2001 | 179 | 74 | 70.48% |
Dec 31, 2000 | 105 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ILMN News
- 7 days ago - Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript) - Seeking Alpha
- 7 days ago - Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025 - PRNewsWire
- 8 days ago - Illumina and NVIDIA collaborate to decode biology and propel precision health - PRNewsWire
- 8 days ago - Truveta sells stakes to Regeneron, Illumina in deal to build genetic database - Reuters
- 8 days ago - Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples - PRNewsWire
- 12 days ago - Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025 - PRNewsWire
- 14 days ago - Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications - PRNewsWire
- 5 weeks ago - Ovation.io and Illumina Collaborate to Advance Genomic Data Research - Business Wire